Goran Jankovic

Jasmina Simonovic-Babic

Ksenija Bojovic

Maja Jovanovic

Milotka Fabri

Petar Svorcan

Velimir Kostic

Zeljko Mijailovic

Srpski Arhiv za Celokupno Lekarstvo

Introduction. The triple therapy which consists of one of the protease
   inhibitor plus pegylated interferon and ribavirin (P/R) is the standard of
   care for the treatment of chronic hepatitis C virus (HCV) genotype 1(G1)
   infection both in treatment-na?ve and experienced patients. Objective. The
   aim of this study was to analyze the efficacy and tolerability of this regime
   in hospital practice in Serbia. Methods. From July 2012 to October 2012, 20
   previously treated patients with advanced fibrosis and HCV G1 infection were
   included in the triple antiviral regimen in six referral centers in Serbia.
   All patients were treated with response guide therapy (RGT) regime according
   to the boceprevir treatment protocol. During the 4-week lead-in period all
   patients received peginterferon plus ribavirin. After the lead-in period
   boceprevir was added in the dosage of 800 mg three times a day orally. The
   subsequent treatment varied according to virologic response and fibrosis.
   During the therapy HCV RNA level was measured at week 4, 8, 12, 24 of the
   treatment for the assessment of virologic response profile. All patients who
   completed therapy were assessed at the end of the treatment and at the end of
   an additional 24-week treatment-free period for a sustained virologic
   response (SVR). Results. The total of 20 patients with advanced fibrosis was
   treated. Among patients with an undetectable HCV RNA level at week 8 the rate
   of SVR was 100%. No patient with decrease in the HCV RNA level &lt;1 log 10
   IU/ml at treatment week 4 achieved SVR. The overall rate of SVR was 55%. The
   safety profile of the treatment regimen was good. Anemia was reported in 25%
   of patients. There was no life-threatening treatment adverse event.
   Conclusion. Boceprevir in combination with P/R achieved fairly good SVR rates
   in patients that were ?most difficult to treat? who failed on dual therapy
   and was effective among patients with cirrhosis.</jats:p

Crossref

Srpski arhiv za celokupno lekarstvo

Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia

Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia

Abstract

Similar works

Full text

Available Versions

Crossref